Michael A. Bolognese - Publications

Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density.

Journal: JBMR plus

Published: March 10, 2025

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: May 08, 2021

Skeletal responses to romosozumab after 12 months of denosumab.

Journal: JBMR plus

Published: January 13, 2021

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: June 11, 2019

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: October 18, 2017

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: January 24, 2017

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: December 22, 2016

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.

Journal: BMC musculoskeletal disorders

Published: November 30, 2016

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 09, 2016

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: March 08, 2016

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: June 12, 2015

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 22, 2015